Pricing Log in Create free account
Friday 6 November 2026 Export CYTK’s income statement to Excel — free account

Cytokinetics, Incorporated

CYTK Healthcare Biotechnology

Cytokinetics, Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $88.0 million, up 376.6% from fiscal 2024.

Revenue
+2,356.5%
EPS
+46.3%
Free cash flow
−6.73%
Total debt
−83.9%

Quarter to September 2026, against a year earlier

54.95 0.60 −1.08%
Market cap
$7.7B
P/E
0.0×
Fwd P/E
−10.3×
Dividend yield
—
F-score
2/9
Altman Z
−1.98
Beneish M
−0.44
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Cytokinetics, Incorporated (CYTK) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
10-Q Sep 30, 2026 P1I2: 5 added · 34 modified
P2I1A: no comparison — the earlier filing's Item cannot be compared 		Short cash runway Share dilution
8-K Nov 4, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Aug 28, 2026 8.01 Other events; 9.01 Financial statements and exhibits
8-K Aug 13, 2026 8.01 Other events
10-Q Jun 30, 2026 P1I2: 6 added · 15 removed · 45 modified
P2I1A: no comparison — incorporated by reference
8-K Aug 6, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K May 27, 2026 5.07 Submission of matters to a vote of security holders
8-K May 6, 2026 8.01 Other events; 9.01 Financial statements and exhibits
8-K May 5, 2026 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Mar 31, 2026
8-K May 5, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Dec 31, 2025 1: 60 added · 17 removed · 62 modified
1A: 15 added · 9 removed · 59 modified
7: 21 added · 14 removed · 46 modified
8-K Feb 24, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Feb 17, 2026 8.01 Other events
8-K Dec 19, 2025 8.01 Other events
8-K Dec 12, 2025 8.01 Other events
8-K Nov 13, 2025 5.02 Departure or appointment of directors or officers Officer departure
10-Q Sep 30, 2025
8-K Nov 5, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Sep 16, 2025 1.01 Entry into a material definitive agreement; 2.03 Creation of a direct financial obligation; 3.02 Unregistered sales of equity securities; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Sep 15, 2025 8.01 Other events
8-K/A Aug 31, 2025 8.01 Other events; 9.01 Financial statements and exhibits
8-K Aug 31, 2025 8.01 Other events; 9.01 Financial statements and exhibits
8-K Aug 30, 2025 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025
8-K Aug 7, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Mar 31, 2025
8-K May 6, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Dec 31, 2024
8-K Feb 27, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Sep 30, 2024
10-Q Jun 30, 2024
8-K Aug 8, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K May 8, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Feb 27, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.